Company intelligence / Profile preview

Phycoil Biotechnology

Fremont, California, United States

Ownership: Private
Development stage: Other

Overview

Phycoil has developed a proprietary microbial fermentation platform to produce rare and optimized omega fatty acids from microalgae. Their lead portfolio includes high-purity DHA/EPA oils with preclinical validation in cardiovascular, cognitive, and inflammatory indications. Commercialization of their lead formulation is expected after initial clinical validation studies planned for Q3 2025.

Therapeutic areas: ImmunologyNeurologyCardiovascular
Modalities: Lipid-based bioactives (e.g., omega fatty acids)Microbial fermentation-derived ingredients
Industry: Biotech

Partnerships

Not specifically disclosed; seeking strategic licensing/commercial partnerships in nutraceuticals and functional foods sectors.PBK collaborates on manufacturing scale-up.

Beyond the preview

Go deeper on Phycoil Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phycoil Biotechnology.

Explore the full profile